Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of advanced or metastatic solid tumor.~* Measurable disease per Response Criteria in Solid Tumors (RECIST criteria).~* Incurable cancer, with disease progression following at least 1 conventional or standard therapy for locally advanced or metastatic disease.~* Negative pregnancy test for women of child bearing potential.~Exclusion Criteria:~* Chronic treatment with corticosteroids.~* Primary central nervous system (CNS) tumors and active metastases.~* Presence of clinically significant or uncontrolled cardiac disease.~* Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom.~* Symptomatic or prior history of non-infectious interstitial pneumonitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neratinib and Temsirolimus (Dose level 1) (Type: EXPERIMENTAL): Neratinib 120 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 2) (Type: EXPERIMENTAL): Neratinib 120 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 3) (Type: EXPERIMENTAL): Neratinib 120 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 4) (Type: EXPERIMENTAL): Neratinib 120 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 5) (Type: EXPERIMENTAL): Neratinib 160 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 6) (Type: EXPERIMENTAL): Neratinib 160 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 7) (Type: EXPERIMENTAL): Neratinib 160 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 8) (Type: EXPERIMENTAL): Neratinib 160 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 9) (Type: EXPERIMENTAL): Neratinib 200 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 10) (Type: EXPERIMENTAL): Neratinib 200 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 11) (Type: EXPERIMENTAL): Neratinib 200 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
- Neratinib and Temsirolimus (Dose level 12) (Type: EXPERIMENTAL): Neratinib 240 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete